Treatment of breathing difficulties with Covid-19
The Bavarian Research Foundation supports a new research approach for the treatment of breathing disorders in Covid-19.
Treatment of breathing difficulties with Covid-19
The Bavarian Research Foundation supports a new research approach for the treatment of breathing disorders in Covid-19.
Funding of the project
With almost half a million euros, the Bavarian Research Foundation will fund a project that ISAR Bioscience will carry out together with the Institute for Pharmacology and Toxicology at the Technical University of Munich. The aim is to develop a completely new therapy for pulmonary fibrosis, which can develop as a result of severe courses of the Covid 19 disease. Affected patients often complain of breathing difficulties and shortness of breath. The symptoms are presumably triggered by a pathological increase in connective tissue in the lungs – a process that impairs the transfer of oxygen into the blood. Scientists of Prof. Dr. Dr. Stefan Engelhardt’s research team and of ISAR Bioscience aim to suppress the connective tissue proliferation in the lungs with completely new therapeutics and thus alleviate the Covid 19-induced breathing difficulties.
